[go: up one dir, main page]

RU2001118839A - ANALOGUES GPP-1 - Google Patents

ANALOGUES GPP-1

Info

Publication number
RU2001118839A
RU2001118839A RU2001118839/04A RU2001118839A RU2001118839A RU 2001118839 A RU2001118839 A RU 2001118839A RU 2001118839/04 A RU2001118839/04 A RU 2001118839/04A RU 2001118839 A RU2001118839 A RU 2001118839A RU 2001118839 A RU2001118839 A RU 2001118839A
Authority
RU
Russia
Prior art keywords
ala
hgpp
seq
pal
aib
Prior art date
Application number
RU2001118839/04A
Other languages
Russian (ru)
Other versions
RU2208015C2 (en
Inventor
Женг Ксин Донг
Дэвид Х. КОЙ
Original Assignee
Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас
Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас, Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд filed Critical Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас
Publication of RU2001118839A publication Critical patent/RU2001118839A/en
Application granted granted Critical
Publication of RU2208015C2 publication Critical patent/RU2208015C2/en

Links

Claims (12)

1. Соединение формулы (I)1. The compound of formula (I) (R2R3)-А7-А8-А9-А10-А11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-R1, (I)(R 2 R 3 ) -A 7 -A 8 -A 9 -A 10 -A 11 -A 12 -A 13 -A 14 -A 15 -A 16 -A 17 -A 18 -A 19 -A 20 -A 21 -A 22 -A 23- A 24 -A 25 -A 26 -A 27 -A 28 -A 29 -A 30 -A 31 -A 32 -A 33 -A 34 -A 35 -A 36 -A 37 - R 1 , (I) где А7 представляет собой L-His, Ura, Paa, Pta, D-His, Tyr, 3-Pal, 4-Pal, Hppa, Tma-His, Amp или делетирована, при условии, что если А7 представляет собой Ura, Paa, Pta или Hppa, то R2 и R3 делегированы;where A 7 represents L-His, Ura, Paa, Pta, D-His, Tyr, 3-Pal, 4-Pal, Hppa, Tma-His, Amp or is deleted, provided that if A 7 represents Ura, Paa, Pta or Hppa, then R 2 and R 3 are delegated; А8 означает Ala, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala, Arg или N-Me-Gly;A 8 is Ala, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala, Arg or N-Me-Gly; А9 означает Glu, N-Me-Glu, N-Me-Asp или Asp;And 9 means Glu, N-Me-Glu, N-Me-Asp or Asp; А10 означает Gly, Acc, Ala, D-Ala, Phe или Aib;And 10 means Gly, Acc, Ala, D-Ala, Phe or Aib; A11 означает Thr или Ser;A 11 means Thr or Ser; А12 означает Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, β-Nal, Cha, Trp или Xl-Phe;And 12 is Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, β-Nal, Cha, Trp or X 1 -Phe; А13 означает Thr или Ser;A 13 means Thr or Ser; А14 означает Ser, Thr, Ala или Aib;A 14 is Ser, Thr, Ala or Aib; А15 означает Asp, Ala, D-Asp или Glu;A 15 is Asp, Ala, D-Asp or Glu; А16 означает Val, D-Val, Acc, Aib, Leu, Ile. Tle, Nle, Abu, Ala, D-Ala, Tba или Cha;And 16 means Val, D-Val, Acc, Aib, Leu, Ile. Tle, Nle, Abu, Ala, D-Ala, Tba or Cha; А17 означает Ser, Ala, D-Ala, Aib, Acc или Thr;A 17 is Ser, Ala, D-Ala, Aib, Acc or Thr; А18 означает Ser, Ala, D-Ala, Aib, Acc или Thr;A 18 is Ser, Ala, D-Ala, Aib, Acc or Thr; А19 означает Tyr, D-Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal, Amp или X1-Phe;And 19 means Tyr, D-Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal, Amp or X 1 -Phe; А20 означает Leu, Ala, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe или X1-Phe;And 20 means Leu, Ala, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X 1 -Phe; А21 означает Glu, Ala или Asp;A 21 means Glu, Ala or Asp; А22 означает Gly, Acc, Ala, D-Ala, β-Ala или Aib;A 22 means Gly, Acc, Ala, D-Ala, β-Ala or Aib; А23 означает Gln, Asp, Ala, D-Ala, Aib, Acc, Asn или Glu;A 23 means Gln, Asp, Ala, D-Ala, Aib, Acc, Asn or Glu; А24 означает Ala, Aib, Val, Abu, Tle или Acc;A 24 means Ala, Aib, Val, Abu, Tle or Acc; А25 означает Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH((CH2)n-NR10R11)-С(О) или HN-CH((CH2)e-X3)-С(О);A 25 means Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH ((CH 2 ) n -NR 10 R 11 ) -C (O) or HN-CH ((CH 2 ) e —X 3 ) —C (O); А26 означает Lys, Ala, 3-Pal, 4-Pal, Arg, hArg, Orn, Amp, HN-CH((CH2)n-NR10R11-C(O) или HN-CH((СН2)е-Х3)-С(О);A 26 means Lys, Ala, 3-Pal, 4-Pal, Arg, hArg, Orn, Amp, HN-CH ((CH 2 ) n -NR 10 R 11 -C (O) or HN-CH ((CH 2 ) e -X 3 ) -C (O); А27 означает Glu, Ala, D-Ala или Asp;A 27 means Glu, Ala, D-Ala or Asp; А28 означает Phe, Ala, Pal, β-Nal, Xl-Phe, Aic, Acc, Aib, Cha или Trp;A 28 means Phe, Ala, Pal, β-Nal, X 1 -Phe, Aic, Acc, Aib, Cha or Trp; А29 означает Ile. Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala, Tba или Phe;A 29 means Ile. Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala, Tba or Phe; А30 означает Ala, Aib, Acc или делетирована;And 30 means Ala, Aib, Acc or deleted; А31 означает Trp, Ala, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib, Cha, Amp или делетирована;A 31 means Trp, Ala, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib, Cha, Amp or is deleted; А32 означает Leu, Ala, Acc, Aib, Nle, Ile, Cha, Tle, Phe, Xl-Phe, Ala или делетирована;A 32 means Leu, Ala, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X 1 -Phe, Ala or is deleted; А33 означает Val, Acc, Aib, Leu, Ile. Tle, Nle, Cha, Ala, Phe, Abu, Xl-Phe, Tba, Gaba или делетирована;And 33 means Val, Acc, Aib, Leu, Ile. Tle, Nle, Cha, Ala, Phe, Abu, X l -Phe, Tba, Gaba or deleted; А34 означает Lys, Arg, hArg, Orn, Amp, Gaba, HN-CH((CH2)n-NR10R11)-C(O), HN-CH((СН2)е-X3)-С(O) или делетирована;A 34 means Lys, Arg, hArg, Orn, Amp, Gaba, HN-CH ((CH 2 ) n -NR 10 R 11 ) -C (O), HN-CH ((CH 2 ) e -X 3 ) - C (O) or deleted; А35 означает Gly или делетирована;A 35 means Gly or deleted; А36 означает L- или D-Arg, D- или L-Lys, D- или L-hArg, D- или L-Orn, Amp, HN-CH ((CH2)n-NR10R11)-С(О), HN-CH((CH2)e-X3)-С(О) или делетирована;A 36 is L- or D-Arg, D- or L-Lys, D- or L-hArg, D- or L-Orn, Amp, HN-CH ((CH 2 ) n -NR 10 R 11 ) -C (O), HN — CH ((CH 2 ) e —X 3 ) —C (O) or deleted; А37 означает Gly или делетирована;A 37 means Gly or deleted; X1 в каждом случае независимо выбран из группы, состоящей из (C1-С6) алкила, ОН и галогена;X 1 in each case is independently selected from the group consisting of (C 1 -C 6 ) alkyl, OH and halogen; R1 означает ОН, NH2, (C1-C12) алкоксигруппу или NH-X2-CH2-Z0, где Х2 является (C1-C12) углеводородным фрагментом и Z0 представляет собой Н, ОН, CO2H или CONH2;R 1 is OH, NH 2 , (C 1 -C 12 ) alkoxy, or NH-X 2 -CH 2 -Z 0 , where X 2 is a (C 1 -C 12 ) hydrocarbon moiety and Z 0 is H, OH, CO 2 H or CONH 2 ; X3 означаетX 3 means
Figure 00000001
Figure 00000001
 или -C(O)-NHR12, где X4 в каждом случае независимо представляет собой -С(О)-, -NH-C(O)- или -СН2-; f в каждом случае независимо является целым числом от 1 до 29;or —C (O) —NHR 12 , wherein X 4 in each case independently is —C (O) -, —NH — C (O) -, or —CH 2 -; f in each case is independently an integer from 1 to 29; каждый из радикалов R2 и R3 независимо выбран из группы, состоящей из Н, (С1-С30)алкила, (С2-С30)алкенила, фенил(C1-С30)алкила, нафтил(C1-С30)алкила, гидрокси(C1-С30)алкила, гидрокси(C2-С30)алкенила, гидроксифенил(C1-С30)алкила и гидроксинафтил(C1-С30)алкила; или один из радикалов R2 и R3 означает С(O)Х5, в котором X5 является (C1-С30)алкилом, (С2-С30)алкенилом, фенил(C1-С30)алкилом, нафтил(C1-С30)алкилом, гидрокси(C2-С30)алкилом, гидрокси(C2-С30)алкенилом, гидроксифенил(C1-С30)алкилом, гидроксинафтил(C1-С30)алкилом,each of the radicals R 2 and R 3 is independently selected from the group consisting of H, (C 1 -C 30 ) alkyl, (C 2 -C 30 ) alkenyl, phenyl (C 1 -C 30 ) alkyl, naphthyl (C 1 - C 30 ) alkyl, hydroxy (C 1 -C 30 ) alkyl, hydroxy (C 2 -C 30 ) alkenyl, hydroxyphenyl (C 1 -C 30 ) alkyl and hydroxy-naphthyl (C 1 -C 30 ) alkyl; or one of the radicals R 2 and R 3 means C (O) X 5 in which X 5 is (C 1 -C 30 ) alkyl, (C 2 -C 30 ) alkenyl, phenyl (C 1 -C 30 ) alkyl, naphthyl (C 1 -C 30) alkyl, hydroxy (C 2 -C 30) alkyl, hydroxy (C 2 -C 30) alkenyl, hydroxyphenyl (C 1 -C 30) alkyl, hydroxynaphthyl (C 1 -C 30) alkyl,
Figure 00000002
Figure 00000002
Figure 00000003
Figure 00000003
Figure 00000004
Figure 00000004
 где Y означает Н или ОН, r = 0-4 и q = 0-4;where Y is H or OH, r = 0-4 and q = 0-4; е независимо для каждого случая является целым числом от 1 до 4;e independently for each case is an integer from 1 to 4; n независимо для каждого случая является целым числом от 1 до 5;n independently for each case is an integer from 1 to 5; R10 и R11 независимо в каждом случае означают Н, (C1-С30)-алкил, (C1-С30)ацил, (C1-С30)алкилсульфонил, -С((NH)(NH2)) илиR 10 and R 11 independently in each case mean H, (C 1 -C 30 ) -alkyl, (C 1 -C 30 ) acyl, (C 1 -C 30 ) alkylsulfonyl, -C ((NH) (NH 2 ) ) or
Figure 00000005
Figure 00000005
 при условии, что когда R10 является (С1-С30)ацилом, (C1-С30)-алкилсульфонилом, -С((NH)(NH2)) илиwith the proviso that when R 10 is (C 1 -C 30 ) acyl, (C 1 -C 30 ) -alkylsulfonyl, -C ((NH) (NH 2 )) or
Figure 00000006
Figure 00000006
 R11 представляет собой Н или (C1-С30)алкил;R 11 represents H or (C 1 -C 30 ) alkyl; R12 является (C1-С30)алкилом;R 12 is (C 1 -C 30 ) alkyl; при условии, что: (i) по меньшей мере одна аминокислота соединения формулы (I) не та же самая, что и в нативной последовательности чГПП-1(7-36 или -37)NH2 (SEQ ID NO: 1,2) или чГПП-1(7-36 или -37)ОН (SEQ ID NO: 3,4);.(ii) соединение формулы (I) не является аналогом чГПП-1(7-36 или -37)NH2 (SEQ ID NO: 1,2) или чГПП-1(7-36 или -37)ОН (SEQ ID NO: 3,4), где одно положение замещено Ala; (iii) соединение формулы (I) не является [Lys26(Nεалканоил)]чГПП-1(7-36 или -37)-Е (SEQ ID NO:5-8), [Lys34 (Nεалканоил)]чГПП-1 (7-36 или -37)-E (SEQ ID NO:9-12), [Lys26,34-бис(Nε-алканоил)]чГПП-1 (7-36 или -37)-Е (SEQ ID NO: 13-16), [Arg26, Lys34(Nε-алканоил)]чГПП-1 (8-36 или -37)-E (SEQ ID NO: 17-20) или [Arg26,34, Lys36(Nε-алканоил)]чГПП-1(7-36 или -37)-E, где Е означает -ОН или -NH2 (SEQ ID NO: 21-24); (iv) соединение формулы (I) не является Z1-чГПП-1(7-36 или -37)-ОН, Z1-чГПП-1(7-36 или -37)-NH2, где Z1 выбран из группы, состоящей изprovided that: (i) at least one amino acid of the compound of formula (I) is not the same as in the native hGPP-1 (7-36 or -37) NH 2 sequence (SEQ ID NO: 1,2) or hGPP-1 (7-36 or -37) OH (SEQ ID NO: 3,4);. (ii) the compound of formula (I) is not an analogue of hGPP-1 (7-36 or -37) NH 2 (SEQ ID NO: 1,2) or hGPP-1 (7-36 or -37) OH (SEQ ID NO: 3,4), where one position is replaced by Ala; (iii) the compound of formula (I) is not [Lys 26 (Nε alkanoyl)] hGPP-1 (7-36 or -37) -E (SEQ ID NO: 5-8), [Lys 34 (Nε alkanoyl)] hGPP-1 (7-36 or -37) -E (SEQ ID NO: 9-12), [Lys 26.34 bis (Nε-alkanoyl)] hGPP-1 (7-36 or -37) -E (SEQ ID NO : 13-16), [Arg 26 , Lys 34 (Nε-alkanoyl)] hGPP-1 (8-36 or -37) -E (SEQ ID NO: 17-20) or [Arg 26.34 , Lys 36 ( Nε-alkanoyl)] hGPP-1 (7-36 or -37) -E, where E is —OH or —NH 2 (SEQ ID NO: 21-24); (iv) the compound of formula (I) is not Z 1 -hGPP-1 (7-36 or -37) -OH, Z 1 -hGPP-1 (7-36 or -37) -NH 2 , where Z 1 is selected from a group consisting of (a) [Arg26] (SEQ ID NO: 25-28), [Arg34] (SEQ ID NO: 29-32), [Arg26,34] (SEQ ID NO: 33-36), [Lys36] (SEQ ID NO: 37-40), [Arg26, Lys36] (SEQ ID NO: 41-44), [Arg34, Lys36] (SEQ ID NO: 45-46), [D-Lys36], [Arg36] (SEQ ID NO: 37-40), [D-Arg36], [Arg26,34, Lys36] (SEQ ID NO: 49-52) или [Arg26,36, Lys34] (SEQ ID NO: 25-28); (b) [Asp21] (SEQ ID NO: 53-56); (c) по меньшей мере одного из [Aib8] (SEQ ID NO: 57-60), [D-Ala8] и [Asp9] (SEQ ID NO: 61-64); и (d) [Tyr7] (SEQ ID NO: 65-68), [N-ацил-His7] (SEQ ID NO: 69-72), [N-алкил-His7] (SEQ ID NO: 73-76), [N-ацил-D-His7] или [N-алкил-D-His7];(a) [Arg 26 ] (SEQ ID NO: 25-28), [Arg 34 ] (SEQ ID NO: 29-32), [Arg 26.34 ] (SEQ ID NO: 33-36), [Lys 36 ] (SEQ ID NO: 37-40), [Arg 26 , Lys 36 ] (SEQ ID NO: 41-44), [Arg 34 , Lys 36 ] (SEQ ID NO: 45-46), [D-Lys 36 ], [Arg 36 ] (SEQ ID NO: 37-40), [D-Arg 36 ], [Arg 26.34 , Lys 36 ] (SEQ ID NO: 49-52) or [Arg 26.36 , Lys 34 ] (SEQ ID NO: 25-28); (b) [Asp 21 ] (SEQ ID NO: 53-56); (c) at least one of [Aib 8 ] (SEQ ID NO: 57-60), [D-Ala 8 ] and [Asp 9 ] (SEQ ID NO: 61-64); and (d) [Tyr 7 ] (SEQ ID NO: 65-68), [N-acyl-His 7 ] (SEQ ID NO: 69-72), [N-alkyl-His 7 ] (SEQ ID NO: 73 -76), [N-acyl-D-His 7 ] or [N-alkyl-D-His 7 ]; (v) соединение формулы (I) не является комбинацией любых из двух замещений, перечисленных в группах от (а) до (d); и (vi) соединение формулы (I) не является [N-Me-Ala8]чГПП-1(8-36 или -37) (SEQ ID NO: 77,78), [Glu15] чГПП-1(7-36 или -37) (SEQ ID NO: 79,80), [Asp21] чГПП-1(7-36 или -37) (SEQ ID NO: 53,54) или [Phe31]чГПП-1(7-36 или -37) (SEQ ID NO: 81,82).(v) the compound of formula (I) is not a combination of any of the two substitutions listed in groups (a) to (d); and (vi) the compound of formula (I) is not [N-Me-Ala 8 ] hGPP-1 (8-36 or -37) (SEQ ID NO: 77.78), [Glu 15 ] hGPP-1 (7- 36 or -37) (SEQ ID NO: 79.80), [Asp 21 ] hGPP-1 (7-36 or -37) (SEQ ID NO: 53.54) or [Phe 31 ] hGPP-1 (7- 36 or -37) (SEQ ID NO: 81.82). 2. Соединение по п.1 или его фармацевтически приемлемая соль, где А11 представляет собой Thr; А13 означает Thr; А14 означает Ser, Aib или Ala; А17 означает Ser, Ala, Aib или D-Ala; А18 означает Ser, Ala, Aib или D-Ala; А21 означает Glu или Ala; А23 означает Gin, Glu или Ala; и А27 означает Glu или Ala.2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A 11 is Thr; A 13 means Thr; A 14 is Ser, Aib or Ala; And 17 means Ser, Ala, Aib or D-Ala; A 18 is Ser, Ala, Aib or D-Ala; A 21 means Glu or Ala; A 23 means Gin, Glu or Ala; and A 27 means Glu or Ala. 3. Соединение по п.2 или его фармацевтически приемлемая соль, где А9 представляет собой Glu, N-Me-Glu или N-Me-Asp; A12 означает Phe, Acc или Aic; А16 означает Val, D-Val, Acc, Aib, Ala, Tle или D-Ala; А19 означает Tyr, 3-Pal, 4-Pal или D-Tyr; А20 означает Leu, Acc, Cha, Ala или Tle; А24 означает Ala, Aib или Acc; А25 означает Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH((CH2)n-NH-R10-C(O); А28 означает Phe или Ala; А29 означает Ile, Acc или Tle; А30 означает Ala, Aib или делетирована; А31 означает Trp, Ala, 3-Pal, 4-Pal или делетирована; А32 означает Leu, Acc, Cha, Ala или делетирована; А33 означает Val, Асс, Ala, Gaba, Tle или делетирована.3. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein A 9 is Glu, N-Me-Glu or N-Me-Asp; A 12 means Phe, Acc or Aic; A 16 means Val, D-Val, Acc, Aib, Ala, Tle or D-Ala; And 19 is Tyr, 3-Pal, 4-Pal or D-Tyr; And 20 means Leu, Acc, Cha, Ala or Tle; A 24 means Ala, Aib or Acc; A 25 means Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH ((CH 2 ) n -NH-R 10 -C (O); A 28 means Phe or Ala; A 29 means Ile, Acc or Tle; A 30 means Ala, Aib or deleted; A 31 means Trp, Ala, 3-Pal, 4-Pal or deleted; A 32 means Leu, Acc, Cha, Ala or deleted; A 33 means Val, Ass, Ala , Gaba, tle or deleted. 4. Соединение по п.3 или его фармацевтически приемлемая соль, где А8 представляет собой Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala или N-Me-Gly; А10 означает Gly, Ala, D-Ala или Phe; А12 означает Phe, A6c, или A5c; А16 означает Val, Ala, Tle, A6c, A5c или D-Val; А20 означает Leu, A6c, A5c, Cha, Ala или Tle; А22 означает Gly, Aib, β-Ala, L-Ala или D-Ala; А24 означает Ala или Aib; А29 означает Ile, А6с, А5с или Tle; А32 означает Leu, A6c, A5c, Cha, Ala или делетирована; А33 означает Val, A6c, A5c, Ala, Gaba, Tle или делетирована.4. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein A 8 is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; And 10 means Gly, Ala, D-Ala or Phe; And 12 means Phe, A6c, or A5c; A 16 means Val, Ala, Tle, A6c, A5c or D-Val; And 20 means Leu, A6c, A5c, Cha, Ala or Tle; A 22 means Gly, Aib, β-Ala, L-Ala or D-Ala; A 24 means Ala or Aib; A 29 means Ile, A6c, A5c or Tle; A 32 means Leu, A6c, A5c, Cha, Ala or is deleted; A 33 means Val, A6c, A5c, Ala, Gaba, Tle or deleted. 5. Соединение по п.4 или его фармацевтически приемлемая соль, где R1 представляет собой ОН или NH2.5. The compound according to claim 4 or its pharmaceutically acceptable salt, where R 1 represents OH or NH 2 . 6. Соединение по п.5 или его фармацевтически приемлемая соль, где R2 представляет собой Н и R3 означает (C1-С30)алкил, (С2-С30)алкенил, (C1-С30)ацил,6. The compound according to claim 5 or its pharmaceutically acceptable salt, where R 2 represents H and R 3 means (C 1 -C 30 ) alkyl, (C 2 -C 30 ) alkenyl, (C 1 -C 30 ) acyl,
Figure 00000007
Figure 00000007
Figure 00000008
Figure 00000008
Figure 00000009
Figure 00000009
 7. Соединение по п.1, где указанным соединением является7. The compound according to claim 1, where the specified connection is [D-Ala8, Ala17,22,23,27, 3-Pal19,31, Gaba34]-ГПП-1(7-34)NH2;[D-Ala 8 , Ala 17,22,23,27 , 3-Pal 19,31 , Gaba 34 ] -GPP-1 (7-34) NH 2 ; [D-Ala8,23,27, 3-Pal19,31]чГПП-1(7-35)-NH2;[D-Ala 8.23.27 , 3-Pal 19.31 ] hGPP-1 (7-35) -NH 2 ; [Ala18,23,27, 3-Pal19,31]чГПП-1(7-35)-NH2; (SEQ ID NO: 83);[Ala 18.23.23 , 3-Pal 19.31 ] hGPP-1 (7-35) -NH 2 ; (SEQ ID NO: 83); [Ala16,23,27, 3-Pal19,31]чГПП-1(7-35)-NH2 (SEQ ID NO: 84);[Ala 16.23.23 , 3-Pal 19.31 ] hGPP-1 (7-35) -NH 2 (SEQ ID NO: 84); [Ala14,23,27, 3-Pal19,31]чГПП-1(7-35)-NH2 (SEQ ID NO: 85);[Ala 14.23.23 , 3-Pal 19.31 ] hGPP-1 (7-35) -NH 2 (SEQ ID NO: 85); [Ala22,23,27, 3-Pal19,31]чГПП-1(7-35)-NH2 (SEQ ID NO: 86);[Ala 22.23.23 , 3-Pal 19.31 ] hGPP-1 (7-35) -NH 2 (SEQ ID NO: 86); [Нрра7]чГПП-1(7-36)-NH2 (SEQ ID NO: 87);[Nrra 7 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 87); [Ala15,23,27, 3-Pal19,31]чГПП-1(7-35)-NH2 (SEQ ID NO: 88);[Ala 15.23.23 , 3-Pal 19.31 ] hGPP-1 (7-35) -NH 2 (SEQ ID NO: 88); [Ala17,23,27, 3-Pal19,31]чГПП-1(7-35)-NH2 (SEQ ID NO: 89);[Ala 17.23.23 , 3-Pal 19.31 ] hGPP-1 (7-35) -NH 2 (SEQ ID NO: 89); [Ala22,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2 (SEQ ID NO: 90);[Ala 22.23.23 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 (SEQ ID NO: 90); [Ala15,22,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2 SEQ ID NO: 91);[Ala 15,22,23,27 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 SEQ ID NO: 91); [Ala17,22,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2 SEQ ID NO: 92);[Ala 17,22,23,27 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 SEQ ID NO: 92); [Ala18,22,23,27, 3-Pal19,31, Gaba34]чГПП-l(7-34)-NH2 (SEQ ID NO: 93);[Ala 18,22,23,27 , 3-Pal 19.31 , Gaba 34 ] hGPP-l (7-34) -NH 2 (SEQ ID NO: 93); [Ala21,22,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2 (SEQ ID NO: 94);[Ala 21,22,23,27 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 (SEQ ID NO: 94); [Ala22,23,26,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2 (SEQ ID NO: 95);[Ala 22,23,26,27 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 (SEQ ID NO: 95); [Ala22,23,27,32, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2 (SEQ ID NO: 96);[Ala 22,23,27,32 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 (SEQ ID NO: 96); [Ala22,23,26,27, 3-Pal19,31, Gaba33]чГПП-1(7-33)-NH2 (SEQ ID NO: 97);[Ala 22,23,26,27 , 3-Pal 19.31 , Gaba 33 ] hGPP-1 (7-33) -NH 2 (SEQ ID NO: 97); [Ala22,23,27,31, 3-Pal19, Gaba33]чГПП-1(7-33)-NH2 (SEQ ID NO: 98);[Ala 22,23,27,31 , 3-Pal 19 , Gaba 33 ] hGPP-1 (7-33) -NH 2 (SEQ ID NO: 98); [Ala22,23,27,28, 3-Pal19,31, Gabaзз]чГПП-1(7-33)-NH2 (SEQ ID NO: 99);[Ala 22,23,27,28 , 3-Pal 19.31 , Gaba ss ] hGPP-1 (7-33) -NH 2 (SEQ ID NO: 99); [Ala22,23,27,29, 3-Pal19,31, Gaba]чГПП-1(7-33)-NH2 (SEQ ID NO: 100);[Ala 22,23,27,29 , 3-Pal 19.31 , Gaba] hGPP-1 (7-33) -NH 2 (SEQ ID NO: 100); [Ala23,27, 3-Pal19,31, Gabaзз]чГПП-1(7-33)-NH2 (SEQ ID NO: 101);[Ala 23.27 , 3-Pal 19.31 , Gaba ss ] hGPP-1 (7-33) -NH 2 (SEQ ID NO: 101); [Ala20,22,23,27, 3-Pal19,31, Gabaзз]чГПП-1(7-33)-NH2 (SEQ ID NO: 102);[Ala 20,22,23,27 , 3-Pal 19.31 , Gaba ss ] hGPP-1 (7-33) -NH 2 (SEQ ID NO: 102); [Ala22,23,27, 3-Pal19,31, Gaba33]чГПП-1(7-33)-NH2 (SEQ ID NO: 103);[Ala 22.23.27 , 3-Pal 19.31 , Gaba 33 ] hGPP-1 (7-33) -NH 2 (SEQ ID NO: 103); [Ala17,22,23,27, 3-Pal19,31, Gabaзз]чГПП-1(7-33)-NH2 (SEQ ID NO: 104);[Ala 17,22,23,27 , 3-Pal 19.31 , Gaba ss ] hGPP-1 (7-33) -NH 2 (SEQ ID NO: 104); [D-Ala10, Ala22,23,27, 3-Pal19,31, Gaba33]чГПП-1(7-33)-NH2;[D-Ala 10 , Ala 22,23,27 , 3-Pal 19,31 , Gaba 33 ] hGPP-1 (7-33) -NH 2 ; [D-Ala8, Ala17,23,27, 3-Pal19,31]чГПП-1(7-34)-NH2;[D-Ala 8 , Ala 17.23.23 , 3-Pal 19.31 ] hGPP-1 (7-34) -NH 2 ; [Ala17,23,27, 3-Pal19,26,31]чГПП-1(7-34)-NH2; (SEQ ID NO: 105);[Ala 17.23.23 , 3-Pal 19.26.31 ] hGPP-1 (7-34) -NH 2 ; (SEQ ID NO: 105); [D-Ala8, Ala17, 3-Pal19,31]чГПП-1(7-34)-NH2;[D-Ala 8 , Ala 17 , 3-Pal 19.31 ] hGPP-1 (7-34) -NH 2 ; [Ala17,23,27, 3-Pal19,31]чГПП-1(7-34)-NH2; (SEQ ID NO: 106);[Ala 17.23.23 , 3-Pal 19.31 ] hGPP-1 (7-34) -NH 2 ; (SEQ ID NO: 106); [D-Ala8, Ala17,23,27, 3-Pal19,31, Tle29]чГПП-1(7-34)-NH2;[D-Ala 8 , Ala 17.23.23 , 3-Pal 19.31 , Tle 29 ] hGPP-1 (7-34) -NH 2 ; [D-Ala8, Ala17,23,27, 3-Pal19,31, Tle16]чГПП-1(7-34)-NH2;[D-Ala 8 , Ala 17,23,27 , 3-Pal 19,31 , Tle 16 ] hGPP-1 (7-34) -NH 2 ; [D-Ala8, Ala17,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2;[D-Ala 8 , Ala 17,23,27 , 3-Pal 19,31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 ; [D-Ala22, Ala17,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2;[D-Ala 22 , Ala 17.23.23 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 ; [Aib8, Ala17,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2 (SEQ ID NO: 107);[Aib 8 , Ala 17,23,27 , 3-Pal 19,31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 (SEQ ID NO: 107); [D-Ala8, Ala17,22,23,27, 3-Pal19,31]чГПП-1(7-33)-NH2;[D-Ala 8 , Ala 17,22,23,27 , 3-Pal 19,31 ] hGPP-1 (7-33) -NH 2 ; [Aib8, Ala17,22,23,27, 3-Pal19,31]чГПП-1(7-33)-NH2; (SEQ ID NO: 108);[Aib 8 , Ala 17,22,23,27 , 3-Pal 19,31 ] hGPP-1 (7-33) -NH 2 ; (SEQ ID NO: 108); [Ala17,18,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2 (SEQ ID NO: 109);[Ala 17,18,23,27 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 (SEQ ID NO: 109); [Ala17,23,27, 3-Pal19,31, Tle33, Gaba34]чГПП-1(7-34)-NH2; (SEQ ID NO: 110);[Ala 17,23,27 , 3-Pal 19,31 , Tle 33 , Gaba 34 ] hGPP-1 (7-34) -NH 2 ; (SEQ ID NO: 110); [Tle16, Ala17,23,27, 3-Pal13,31, Gaba34]чГПП-1 (7-34)-NH2 (SEQ ID NO: 111);[Tle 16 , Ala 17.23.23 , 3-Pal 13.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 (SEQ ID NO: 111); [N-Me-D-Ala8, Ala17,22,23,27, 3-Pal19,31]чГПП-1(7-33)-NH2;[N-Me-D-Ala 8 , Ala 17,22,23,27 , 3-Pal 19,31 ] hGPP-1 (7-33) -NH 2 ; [Aib8, Ala17,18,22,23,27, 3-Pal19,31]чГПП-1(7-33)-NH2 (SEQ ID NO: 112);[Aib 8 , Ala 17,18,22,23,27 , 3-Pal 19,31 ] hGPP-1 (7-33) -NH 2 (SEQ ID NO: 112); [Ala17,18,22,23,27, 3-Pal19,31, Tle16,20, Gaba34]чГПП-1(7-34)-NH2 (SEQ ID NO: 113);[Ala 17,18,22,23,27 , 3-Pal 19.31 , Tle 16.20 , Gaba 34 ] hGPP-1 (7-34) -NH 2 (SEQ ID NO: 113); [D-Ala8, Ala17,18,22,23,27, 3-PAl19,31, Tle16, Gaba34]чГПП-1(7-34)-NH2;[D-Ala 8 , Ala 17,18,22,23,27 , 3-PAl 19.31 , Tle 16 , Gaba 34 ] hGPP-1 (7-34) -NH 2 ; [D-Ala8,22, Ala17,18,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2;[D-Ala 8.22 , Ala 17.18.23.23 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 ; [D-Ala8,18, Ala17,22,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2;[D-Ala 8.18 , Ala 17,22,23,27 , 3-Pal 19,31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 ; [D-Ala8,17, Ala18,22,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2; или[D-Ala 8.17 , Ala 18.22 , 23.23 , 3-Pal 19.31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 ; or [D-Ala8, Ala17,18,22,23,27, 3-Pal19,31, Gaba34]чГПП-1(7-34)-NH2;[D-Ala 8 , Ala 17,18,22,23,27 , 3-Pal 19,31 , Gaba 34 ] hGPP-1 (7-34) -NH 2 ; или его фармацевтически приемлемая соль.or a pharmaceutically acceptable salt thereof. 8. Соединение по п.1, где указанным соединением является8. The compound according to claim 1, where the specified connection is [Aib8, А6с32]чГПП-1(7-36)NH2 (SEQ ID NO: 114);[Aib 8 , A6c 32 ] hGPP-1 (7-36) NH 2 (SEQ ID NO: 114); [А6с20,32]чГПП-1(7-36)-NH2 (SEQ ID NO: 115);[A6c 20.32 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 115); [Aib8]чГПП-1(7-36)-NH2 (SEQ ID NO: 116);[Aib 8 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 116); [(Tma-His)7]чГПП-1(7-36)-NH2 (SEQ ID NO: 117);[(Tma-His) 7 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 117); [А6с8]чГПП-1(8-36)-NH2 (SEQ ID NO: 118);[A6c 8 ] hGPP-1 (8-36) -NH 2 (SEQ ID NO: 118); [А6с8]чГПП-1(7-36)-NH2 (SEQ ID NO: 119);[A6c 8 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 119); [А6с16,20]чГПП-1(7-36)-NH2 (SEQ ID NO: 120);[A6c 16.20 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 120); [А6с29,32]чГПП-1(7-36)-NH2 (SEQ ID NO: 121);[A6c 29.32 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 121); [A6c20, Aib24]чГПП-1(7-36)-NH2 (SEQ ID NO: 122);[A6c 20 , Aib 24 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 122); [Aib24, A6c29,32]чГПП-1(7-36)-NH2 (SEQ ID NO: 123);[Aib 24 , A6c 29.32 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 123); [A6c16,29,32]чГПП-1(7-36)-NH2 (SEQ ID NO: 124);[A6c 16,29,32 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 124); [Ura7]чГПП-1(7-36)-NH2 (SEQ ID NO: 125);[Ura 7 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 125); [Раа7]чГПП-1(7-36)-NH2 (SEQ ID NO: 126);[Raa 7 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 126); [Pta7]чГПП-1(7-36)-NH2 (SEQ ID NO: 127);[Pta 7 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 127); [N-Me-Ala8]чГПП-1(7-36)-NH2 (SEQ ID NO: 128);[N-Me-Ala 8 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 128); [N-Me-Ala8]чГПП-1(8-36)-NH2 (SEQ ID NO:);[N-Me-Ala 8 ] hGPP-1 (8-36) -NH 2 (SEQ ID NO :); [N-Me-D-Ala8]чГПП-1(7-36)-NH2;[N-Me-D-Ala 8 ] hGPP-1 (7-36) -NH 2 ; [N-Me-D-Ala8]чГПП-1(8-36)-NH2;[N-Me-D-Ala 8 ] hGPP-1 (8-36) -NH 2 ; [N-Me-Gly8]чГПП-1(7-36)-NH2 (SEQ ID NO: 129);[N-Me-Gly 8 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 129); [А5с8]чГПП-1(7-36)-NH2 (SEQ ID NO: 130);[A5c 8 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 130); [N-Me-Glu9]чГПП-1(7-36)-NH2 (SEQ ID NO: 131);[N-Me-Glu 9 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 131); [A5c8, А6с20,32]чГПП-1(7-36)-NH2 (SEQ ID NO: 132);[A5c 8 , A6c 20.32 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 132); [Aib8, А6с32]чГПП-1(7-36)-NH2 (SEQ ID NO: 133);[Aib 8 , A6c 32 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 133); [Aib8,25]чГПП-1(7-36)-NH2 (SEQ ID NO: 134);[Aib 8.25 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 134); [Aib8,24]чГПП-1(7-36)-NH2 (SEQ ID NO: 135);[Aib 8.24 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 135); [Aib8,30]чГПП-1(7-36)-NH2 (SEQ ID NO: 136);[Aib 8.30 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 136); [Aib8, Cha20]чГПП-1(7-36)-NH2 (SEQ ID NO: 137);[Aib 8 , Cha 20 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 137); [Aib8, Cha32]чГПП-1(7-36)-NH2 (SEQ ID NO: 138);[Aib 8 , Cha 32 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 138); [Aib8, Glu23]чГПП-1(7-36)-NH2 (SEQ ID NO: 139);[Aib 8 , Glu 23 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 139); [Aib8, A6c20]чГПП-1(7-36)-NH2 (SEQ ID NO: 140);[Aib 8 , A6c 20 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 140); [Aib8, А6с20,32]чГПП-1(7-36)-NH2 (SEQ ID NO: 141);[Aib 8 , A6c 20.32 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 141); [Aib8,22]чГПП-1(7-36)-NH2 (SEQ ID NO: 142);[Aib 8.22 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 142); [Aib8, β-Ala22]чГПП-1(7-36)-NH2 SEQ ID NO: 143);[Aib 8 , β-Ala 22 ] hGPP-1 (7-36) -NH 2 SEQ ID NO: 143); [Aib8, Lys25]чГПП-1(7-36)-NH2 (SEQ ID NO: 144);[Aib 8 , Lys 25 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 144); [Aib8, А6с12]чГПП-1(7-36)-NH2 (SEQ ID NO: 145);[Aib 8 , A6c 12 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 145); [Aib8, А6с29]чГПП-1(7-36)-NH2(SEQ ID NO: 146);[Aib 8 , A6c 29 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 146); [Aib8, А6с33]чГПП-1(7-36)-NH2 (SEQ ID NO: 147);[Aib 8 , A6c 33 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 147); [Aib8,14]чГПП-1(7-36)-NH2 (SEQ ID NO: 148);[Aib 8.14 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 148); [Aib8,18]чГПП-1(7-36)-NH2 (SEQ ID NO: 149);[Aib 8.18 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 149); [Aib8,17]чГПП-1(7-36)-NH2 (SEQ ID NO: 150); или[Aib 8.17 ] hGPP-1 (7-36) -NH 2 (SEQ ID NO: 150); or [Aib13, D-Arg26]чГПП-1(7-36)NH2,[Aib 13 , D-Arg 26 ] hGPP-1 (7-36) NH 2 , или его фармацевтически приемлемая соль.or a pharmaceutically acceptable salt thereof. 9. Фармацевтическая композиция, содержащая эффективное количество соединения по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель или разбавитель.9. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent. 10. Способ, позволяющий вызывать под влиянием агониста действие со стороны рецептора ГПП-1 у субъекта, который в этом нуждается, который включает в себя введение указанному субъекту эффективного количества соединения по п.1 или его фармацевтически приемлемой соли.10. A method for causing, under the influence of an agonist, an action on the part of the GLP-1 receptor in a subject who needs it, which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 11. Способ лечения заболевания, выбранного из группы, состоящей из диабета типа I, диабета типа II, ожирения, глюкагономы, секреторных расстройств дыхательных путей, метаболического нарушения, артрита, остеопороза, заболевания центральной нервной системы, рестеноза, нейродегенеративного заболевания, почечной недостаточности, застойной сердечной недостаточности, нефротического синдрома, цирроза, отека легких и гипертензии у субъекта, который в этом нуждается, который включает в себя введение указанному субъекту эффективного количества соединения по п.1 или его фармацевтически приемлемой соли.11. A method of treating a disease selected from the group consisting of type I diabetes, type II diabetes, obesity, glucagonoma, secretory disorders of the respiratory tract, metabolic disorders, arthritis, osteoporosis, central nervous system disease, restenosis, neurodegenerative disease, renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema and hypertension in a subject in need thereof, which includes administering to said subject an effective amount of the unity according to claim 1 or its pharmaceutically acceptable salt. 12. Способ по п.11, при котором указанным заболеванием является диабет типа I или диабет типа II.12. The method according to claim 11, wherein said disease is type I diabetes or type II diabetes.
RU2001118839/04A 1998-12-07 1999-12-07 Glp-1 analogues RU2208015C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20683398A 1998-12-07 1998-12-07
US11118698P 1998-12-07 1998-12-07
US09/206,833 1998-12-07
US60/111,186 1998-12-07

Publications (2)

Publication Number Publication Date
RU2001118839A true RU2001118839A (en) 2003-06-27
RU2208015C2 RU2208015C2 (en) 2003-07-10

Family

ID=26808707

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001118839/04A RU2208015C2 (en) 1998-12-07 1999-12-07 Glp-1 analogues

Country Status (21)

Country Link
US (2) US7368427B1 (en)
EP (2) EP1992641A3 (en)
JP (3) JP2002538081A (en)
KR (1) KR100458748B1 (en)
CN (2) CN101108878B (en)
AT (1) ATE394423T1 (en)
AU (1) AU770609B2 (en)
BR (1) BR9916027A (en)
CA (1) CA2352573C (en)
CZ (2) CZ303120B6 (en)
DE (1) DE69938669D1 (en)
DK (1) DK1137666T5 (en)
ES (1) ES2302390T3 (en)
HU (1) HUP0104579A3 (en)
IL (2) IL143481A0 (en)
NO (2) NO330293B1 (en)
PL (3) PL208751B1 (en)
PT (1) PT1137666E (en)
RU (1) RU2208015C2 (en)
TW (2) TWI339208B (en)
WO (1) WO2000034332A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL208751B1 (en) * 1998-12-07 2011-06-30 Sod Conseils Rech Applic GLP-1 analogues, compositions comprising thereof and the use thereof
KR20050037004A (en) * 1998-12-07 2005-04-20 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Analogues of glp-1
US20030204063A1 (en) * 2000-08-02 2003-10-30 Denis Gravel Modified biological peptides with increased potency
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
JP5161412B2 (en) * 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Methods of using GLP-1 and GLP-2 peptides
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002034285A2 (en) 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
AU2012202081B2 (en) * 2001-07-31 2014-09-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 Exendin-4 peptide analogs and uses thereof
EP2275117B1 (en) 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
EP1572892A4 (en) 2001-10-18 2007-08-22 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2006515271A (en) 2002-07-23 2006-05-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ghrelin analog
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
DE602004025205D1 (en) * 2003-02-19 2010-03-11 Ipsen Pharma GLP-1 Analogs
EP1609855A4 (en) * 2003-03-28 2008-06-11 Nat Inst Of Agrobio Sciences PROCESS FOR PRODUCING PLANT STORAGE ORGAN WITH HIGH PRODUCTION OF RECOMBINANT PROTEINS AND NOVEL RECOMBINANT PROTEIN
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (en) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituted benzoylureido-o-benzoylamides, process for their preparation and their use
ES2393335T3 (en) * 2003-12-16 2012-12-20 Ipsen Pharma GLP-1 analogues
WO2005058252A2 (en) * 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
EP1709071A4 (en) * 2004-01-08 2007-05-30 Theratechnologies Inc PEPTIDE ANALOGUES 1 LIKE LONG-ACTING GLUCAGON-LIKE
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
JP2008543816A (en) * 2005-06-13 2008-12-04 インペリアル イノベーションズ リミテッド Novel compounds and their effects on eating behavior
EP1943275B1 (en) * 2005-11-01 2010-06-16 Activotec SPP Limited Insulinotropic compounds and uses thereof
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
WO2007124461A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2008086086A2 (en) * 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
US20100256056A1 (en) * 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
KR20110039230A (en) * 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon analogues showing enhanced solubility and stability in physiological ｐH buffer
US20110269680A1 (en) * 2008-12-29 2011-11-03 Panacea Biotec Limited Glp-1 analogs and uses thereof
WO2011163012A2 (en) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
JP6007417B2 (en) 2011-05-31 2016-10-12 レセプトス エルエルシー Novel GLP-1 receptor stabilizer and modulator
US8778923B2 (en) 2011-12-12 2014-07-15 Receptos, Inc. GLP-1 receptor modulators
CN102584982B (en) * 2012-02-10 2014-02-05 深圳翰宇药业股份有限公司 Method for purifying solid-phase synthetic coarse liraglutide
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
GEP201706762B (en) * 2013-05-28 2017-10-25 Takeda Pharmaceuticals Co Peptide compound
CN103285379A (en) * 2013-06-09 2013-09-11 南方医科大学 Use of GLP-1 (Glucagon-Like Peptide-1) for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes
WO2014201172A1 (en) 2013-06-11 2014-12-18 Receptos, Inc. Novel glp-1 receptor modulators
WO2016015014A1 (en) 2014-07-25 2016-01-28 Receptos, Inc. Novel glp-1 receptor modulators
JP2018012644A (en) * 2014-11-26 2018-01-25 武田薬品工業株式会社 Peptide compound
MX381977B (en) 2014-12-10 2025-03-13 Receptos Llc GLUCAGON-LIKE PEPTIDE 1 RECEPTOR MODULATORS.
KR20180006881A (en) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. Methods for the treatment of nonalcoholic fatty liver disease and / or fat dystrophy
LT3393496T (en) 2015-12-23 2023-12-11 The Johns Hopkins University Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
US10501516B2 (en) 2016-05-24 2019-12-10 Takeda Pharmaceutical Company Limited Peptide compound
EP3463415A4 (en) * 2016-06-02 2020-03-25 Indiana University Research & Technology Corporation AQUEOUSLY SOLUBLE AND CHEMICALLY STABLE GLUCAGON PEPTIDES
JOP20190177A1 (en) 2017-01-17 2019-07-16 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
AU2018288854B2 (en) 2017-06-20 2025-06-26 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
US12465652B2 (en) 2017-06-21 2025-11-11 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
CN109942696A (en) * 2017-12-21 2019-06-28 中国药科大学 Long-acting glucagon-like peptide-1 (GLP-1) analog and its application
CN116970062B (en) * 2022-04-29 2024-04-09 南京知和医药科技有限公司 Ultra-long acting GLP-1 polypeptide derivative and preparation method and application thereof
KR20250027558A (en) 2022-06-23 2025-02-26 광저우 이노젠 파마슈티컬 그룹 컴퍼니 리미티드 Fusion proteins comprising improved GLP-1 receptor agonists and uses thereof
TW202440649A (en) 2023-03-30 2024-10-16 大陸商廣州銀諾醫藥集團股份有限公司 A pharmaceutical preparation containing GLP-1 fusion protein and its use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1539498A (en) 1925-05-26 And fifteen
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991011454A1 (en) * 1990-01-24 1991-08-08 The Upjohn Company Method of purifying recombinant polypeptides
CA2073856C (en) * 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
DK36392D0 (en) * 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
CZ315594A3 (en) * 1992-06-15 1995-07-12 Pfizer Peptide of glucagon type, insulinotropic derivatives, process of their preparation, pharmaceutical composition containing such compounds and use
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
JP2001503963A (en) * 1996-02-06 2001-03-27 イーライ・リリー・アンド・カンパニー Diabetes treatment
UA72181C2 (en) 1996-08-30 2005-02-15 Ново Нордіск А/С Derivatives of glucanolike peptide-1
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
WO1998043658A1 (en) * 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
FR2777283B1 (en) 1998-04-10 2000-11-24 Adir NOVEL GLUCAGON-PEPTIDE- 1 (7-37) ANALOGUE PEPTIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
PL208751B1 (en) * 1998-12-07 2011-06-30 Sod Conseils Rech Applic GLP-1 analogues, compositions comprising thereof and the use thereof
KR20050037004A (en) 1998-12-07 2005-04-20 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Analogues of glp-1
AU1269501A (en) 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
CN114612953B (en) 2020-12-09 2025-09-26 佳能株式会社 Object recognition model training method and device

Similar Documents

Publication Publication Date Title
RU2001118839A (en) ANALOGUES GPP-1
RU2208015C2 (en) Glp-1 analogues
RU2001118855A (en) ANALOGUES GLP-1
RU2003112447A (en) ANALOGUES GLP-1
AU2023203430B2 (en) Novel glp-1 analogues
CA2122340C (en) Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JP7295871B2 (en) Modified lipidated relaxin B chain peptides and their therapeutic uses
CA2110911A1 (en) Treating disorders by application of insulin-like growth factors and analogs
RU99106518A (en) GLP-1 DERIVATIVES
JP2004131473A5 (en)
CA2378431A1 (en) Peptides that lower blood glucose levels
KR20100038236A (en) Peptide capable of extending half-life of interest in plasma
JP2010535781A (en) Treatment for obesity
JP2018500282A (en) GIP agonist compounds and methods
JPH07116229B2 (en) Peptides with biological activity that are structurally related to regions within growth hormone
JP2010174016A (en) Analogue of glp-1
JPH10512280A (en) Cyclic homologs of PTH and PTHrP
TW201940504A (en) Modified lipidated Relaxin B chain peptides and their therapeutic use
AR043365A1 (en) GLP-1 ANALOGS
CN116970064A (en) GLP-1/GCG receptor co-agonists, pharmaceutical compositions comprising same and uses thereof
Balasubramaniam et al. Structure− activity studies including a ψ (CH2-NH) scan of peptide YY (PYY) active site, PYY (22− 36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine
AR076950A2 (en) ANALOGS OF THE 1-SIMILAR PEPTIDE TO GLUCAGON USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE60109412T2 (en) THERAPEUTIC PEPTIDES
CN116970063A (en) GLP-1/GIP receptor co-agonists, pharmaceutical compositions comprising same and uses thereof
CA2768016A1 (en) Glp-1 analogues